121 related articles for article (PubMed ID: 23374868)
1. 1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl)ethanones as novel CCR1 antagonists.
Pennell AM; Aggen JB; Sen S; Chen W; Xu Y; Sullivan E; Li L; Greenman K; Charvat T; Hansen D; Dairaghi DJ; Wright JJ; Zhang P
Bioorg Med Chem Lett; 2013 Mar; 23(5):1228-31. PubMed ID: 23374868
[TBL] [Abstract][Full Text] [Related]
2. In silico study of 1-(4-Phenylpiperazin-1-yl)-2-(1H-pyrazol-1-yl) ethanones derivatives as CCR1 antagonist: homology modeling, docking and 3D-QSAR approach.
Balasubramanian PK; Balupuri A; Kothandan G; Cho SJ
Bioorg Med Chem Lett; 2014 Feb; 24(3):928-33. PubMed ID: 24424131
[TBL] [Abstract][Full Text] [Related]
3. Discovery and optimization of pyrazole amides as antagonists of CCR1.
Harcken C; Sarko C; Mao C; Lord J; Raudenbush B; Razavi H; Liu P; Swinamer A; Disalvo D; Lee T; Lin S; Kukulka A; Grbic H; Patel M; Patel M; Fletcher K; Joseph D; White D; Amodeo L; Berg K; Brown M; Thomson DS
Bioorg Med Chem Lett; 2019 Feb; 29(3):435-440. PubMed ID: 30455146
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel series of human CCR1 antagonists.
Xie YF; Sircar I; Lake K; Komandla M; Ligsay K; Li J; Xu K; Parise J; Schneider L; Huang D; Liu J; Sakurai N; Barbosa M; Jack R
Bioorg Med Chem Lett; 2008 Mar; 18(6):2215-21. PubMed ID: 18329267
[TBL] [Abstract][Full Text] [Related]
5. N-aryl pyrazoles, indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010/036632, WO2009/134666 and WO2009/137338.
Carter PH; Hynes J
Expert Opin Ther Pat; 2010 Nov; 20(11):1609-18. PubMed ID: 20858032
[TBL] [Abstract][Full Text] [Related]
6. SAR-based optimization of 2-(1H-pyrazol-1-yl)-thiazole derivatives as highly potent EP1 receptor antagonists.
Atobe M; Naganuma K; Kawanishi M; Morimoto A; Kasahara K; Ohashi S; Suzuki H; Hayashi T; Miyoshi S
Bioorg Med Chem Lett; 2013 Dec; 23(24):6569-76. PubMed ID: 24252546
[TBL] [Abstract][Full Text] [Related]
7. Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists.
Elzein E; Kalla R; Li X; Perry T; Parkhill E; Palle V; Varkhedkar V; Gimbel A; Zeng D; Lustig D; Leung K; Zablocki J
Bioorg Med Chem Lett; 2006 Jan; 16(2):302-6. PubMed ID: 16275090
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and structure-activity relationships of zwitterionic spirocyclic compounds as potent CCR1 antagonists.
Hossain N; Ivanova S; Timén ÅS; Bergare J; Mussie T; Bergström L
Bioorg Med Chem Lett; 2013 Jul; 23(14):4026-30. PubMed ID: 23769642
[TBL] [Abstract][Full Text] [Related]
9. Novel pyrrolidine ureas as C-C chemokine receptor 1 (CCR1) antagonists.
Merritt JR; Liu J; Quadros E; Morris ML; Liu R; Zhang R; Jacob B; Postelnek J; Hicks CM; Chen W; Kimble EF; Rogers WL; O'Brien L; White N; Desai H; Bansal S; King G; Ohlmeyer MJ; Appell KC; Webb ML
J Med Chem; 2009 Mar; 52(5):1295-301. PubMed ID: 19183043
[TBL] [Abstract][Full Text] [Related]
10. 1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists.
Tabrizi MA; Baraldi PG; Preti D; Romagnoli R; Saponaro G; Baraldi S; Moorman AR; Zaid AN; Varani K; Borea PA
Bioorg Med Chem; 2008 Mar; 16(5):2419-30. PubMed ID: 18077171
[TBL] [Abstract][Full Text] [Related]
11. The discovery of BMS-457, a potent and selective CCR1 antagonist.
Gardner DS; Santella JB; Duncia JV; Carter PH; Dhar TG; Wu H; Guo W; Cavallaro C; Van Kirk K; Yarde M; Briceno SW; Grafstrom RR; Liu R; Patel SR; Tebben AJ; Camac D; Khan J; Watson A; Yang G; Rose A; Foster WR; Cvijic ME; Davies P; Hynes J
Bioorg Med Chem Lett; 2013 Jul; 23(13):3833-40. PubMed ID: 23707259
[TBL] [Abstract][Full Text] [Related]
12. Novel pyrrolidine heterocycles as CCR1 antagonists.
Merritt JR; James R; Paradkar VM; Zhang C; Liu R; Liu J; Jacob B; Chiriac C; Ohlmeyer MJ; Quadros E; Wines P; Postelnek J; Hicks CM; Chen W; Kimble EF; O'Brien L; White N; Desai H; Appell KC; Webb ML
Bioorg Med Chem Lett; 2010 Sep; 20(18):5477-9. PubMed ID: 20708929
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel azaindazole CCR1 antagonist clinical candidates.
Harcken C; Kuzmich D; Cook B; Mao C; Disalvo D; Razavi H; Swinamer A; Liu P; Zhang Q; Kukulka A; Skow D; Patel M; Patel M; Fletcher K; Sherry T; Joseph D; Smith D; Canfield M; Souza D; Bogdanffy M; Berg K; Brown M
Bioorg Med Chem Lett; 2019 Feb; 29(3):441-448. PubMed ID: 30595446
[TBL] [Abstract][Full Text] [Related]
14. Structure function differences in nonpeptide CCR1 antagonists for human and mouse CCR1.
Onuffer J; McCarrick MA; Dunning L; Liang M; Rosser M; Wei GP; Ng H; Horuk R
J Immunol; 2003 Feb; 170(4):1910-6. PubMed ID: 12574358
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationships of novel, highly potent, selective, and orally active CCR1 antagonists.
Xie YF; Lake K; Ligsay K; Komandla M; Sircar I; Nagarajan G; Li J; Xu K; Parise J; Schneider L; Huang D; Liu J; Dines K; Sakurai N; Barbosa M; Jack R
Bioorg Med Chem Lett; 2007 Jun; 17(12):3367-72. PubMed ID: 17446072
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor.
Chambers LJ; Stevens AJ; Moses AP; Michel AD; Walter DS; Davies DJ; Livermore DG; Fonfria E; Demont EH; Vimal M; Theobald PJ; Beswick PJ; Gleave RJ; Roman SA; Senger S
Bioorg Med Chem Lett; 2010 May; 20(10):3161-4. PubMed ID: 20399651
[TBL] [Abstract][Full Text] [Related]
17. APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology.
Adams JW; Ramirez J; Shi Y; Thomsen W; Frazer J; Morgan M; Edwards JE; Chen W; Teegarden BR; Xiong Y; Al-Shamma H; Behan DP; Connolly DT
J Pharmacol Exp Ther; 2009 Oct; 331(1):96-103. PubMed ID: 19628629
[TBL] [Abstract][Full Text] [Related]
18. CCR1 as a target for multiple myeloma.
Vallet S; Anderson KC
Expert Opin Ther Targets; 2011 Sep; 15(9):1037-47. PubMed ID: 21609295
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists.
Hasui T; Ohyabu N; Ohra T; Fuji K; Sugimoto T; Fujimoto J; Asano K; Oosawa M; Shiotani S; Nishigaki N; Kusumoto K; Matsui H; Mizukami A; Habuka N; Sogabe S; Endo S; Ono M; Siedem CS; Tang TP; Gauthier C; De Meese LA; Boyd SA; Fukumoto S
Bioorg Med Chem; 2014 Oct; 22(19):5428-45. PubMed ID: 25187277
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of endocannabinoid hydrolases FAAH and MAGL inhibitors bearing a benzotriazol-1-yl carboxamide scaffold.
Morera L; Labar G; Ortar G; Lambert DM
Bioorg Med Chem; 2012 Nov; 20(21):6260-75. PubMed ID: 23036333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
